BiotechTube
Pharma Holdings

Pharma Holdings

Oslo, Norway· Est.
pharmaholdings.no
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Pharma Holdings is a clinical-stage biotech developing a novel class of direct-acting virucidal drugs for respiratory infections. Its core technology is the antimicrobial peptide LTX-109, formulated as a nasal spray, which rapidly disrupts viral envelopes. The company is targeting high-risk patient populations for influenza and COVID-like illnesses, with a lead therapeutic program advancing into Phase Ib/IIa trials in 2025. It operates with a lean, virtual model utilizing CROs and CDMOs.

Infectious DiseaseRespiratory

Technology Platform

Antimicrobial peptide (LTX-109) platform with a direct, rapid virucidal mechanism that disrupts viral envelopes. Formulated for topical intranasal delivery to treat infections at the initial site.

Opportunities

The massive global burden of respiratory viral infections and the specific vulnerability of high-risk populations create a significant addressable market.
A successful topical virucide could fulfill a major unmet need for a rapid, mutation-resistant treatment that reduces severe disease progression.

Risk Factors

High clinical development risk as the platform transitions from pre-clinical to human trials.
Facing competition from established systemic antivirals and vaccines.
As a virtual, pre-revenue company, it carries significant financing and execution risk dependent on external partners.

Competitive Landscape

Competes with oral antivirals (e.g., Paxlovid, Tamiflu), vaccines, and other nasal spray products in development. Its key differentiator is the direct, physical virucidal mechanism which may be less susceptible to viral resistance and act faster than inhibitors of viral replication.

More companies in Drug Delivery & Formulation →More companies in Norway →